During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

These findings suggest that targeting PRMT5 signaling in combination with Lenvatinib could be a promising strategy for patients with this specific molecular profile. "We think that patients that ...

The approval is based on the results from the CheckMate-9DW trial, in which 85 percent of patients in the comparator arm were treated with lenvatinib and 15 percent were treated with sorafenib ...